Ironwood Pharmaceuticals | IRWD - Gross Profit On Sales

Stock Price
3.51
Daily Change
0.05 1.45%
Monthly
-3.84%
Yearly
240.78%
Q2 Forecast
3.43

Ironwood Pharmaceuticals reported $85.24M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Almirall EUR 429.87M 180.02M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 23.17M 961K Dec/2025
Ardelyx USD 114.37M 8.02M Dec/2025
Astellas Pharma JPY 456.81B 38.02B Dec/2025
AstraZeneca USD 12.39B 5M Dec/2025
Charles River Laboratories USD 271.96M 39.43M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Moderna USD 226M 583M Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
Pacira USD 142.25M 11.34M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024